杜瓦卢马布
医学
肿瘤科
放射治疗
阶段(地层学)
化疗
内科学
癌症
免疫疗法
古生物学
无容量
生物
作者
Juan Li,Shun Lu,Yuke Tian,Lan Jiang,Lu Li,Shao-Hua Xie,Qiang Li
标识
DOI:10.1016/j.radonc.2024.110316
摘要
This phase Ib study was designed to assess the safety/tolerability and preliminary antitumor activity of neoadjuvant low-dose radiotherapy (LDRT) plus durvalumab and chemotherapy for potentially resectable stage III non-small-cell lung cancer (NSCLC).
科研通智能强力驱动
Strongly Powered by AbleSci AI